3rd ESO–ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3)
Fátima Cardoso, A. Costa, Elżbieta Senkus et al. · The Breast · 2016
Advanced Breast Cancer (ABC) comprises both locally advanced (LABC) and metastatic breast cancer (MBC) [1]. Although treatable, it is remains an incurable disease with a median overall survival of ∼2–3 years and a 5-year survival of only ∼25% [2–4]. Some more recent series seem to indicate an improvement in median overall survival [5,6].
Cited by 228 works. doi:10.1016/j.breast.2016.10.001 Open-access PDF
Authors
- Fátima Cardoso
- A. Costa
- Elżbieta Senkus
- Matti Aapro
- Fabrice André
- Carlos H. Barrios
- Jonas C. S. Bergh
- G.S. Bhattacharyya
- Laura Biganzoli
- LA Carey
- D. Corneliussen-James
- Giuseppe Curigliano
- Veronique C Dieras
- N. El Saghir
- Alexandru E. Eniu
- Lesley J. Fallowfield
- Doris Fenech
- Prudence A. Francis
- Karen A. Gelmon
References
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- Grading Strength of Recommendations and Quality of Evidence in Clinical Guidelines
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
- Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer.
- Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
- Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis
- American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options
- Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
- Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
- A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)